Matt D. Merguerian

Matt D. Merguerian

Hematology

200 North Wolfe Street, Rubenstein BLDG Lower Level
Rubenstein BLDG Lower Level
Baltimore, MD 21287

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 5 publications

Targeting the CD74 signaling axis suppresses inflammation and rescues defective hematopoiesis in RUNX1-familial platelet disorder.

Targeting the CD74 signaling axis suppresses inflammation and rescues defective hematopoiesis in RUNX1-familial platelet disorder.

Journal: Science translational medicine

Published: January 08, 2025

Genomic landscape of patients with germline RUNX1 variants and familial platelet disorder with myeloid malignancy.

Genomic landscape of patients with germline RUNX1 variants and familial platelet disorder with myeloid malignancy.

Journal: Blood advances

Published: July 10, 2023

Genomic Landscape of Patients with Germline RUNX1 Variants and Familial Platelet Disorder with Myeloid Malignancy.

Genomic Landscape of Patients with Germline RUNX1 Variants and Familial Platelet Disorder with Myeloid Malignancy.

Journal: bioRxiv : the preprint server for biology

Published: February 15, 2023

Natural history study of patients with familial platelet disorder with associated myeloid malignancy.

Natural history study of patients with familial platelet disorder with associated myeloid malignancy.

Journal: Blood

Published: January 17, 2023

Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed ALK F1174L-mutated neuroblastoma.

Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed ALK F1174L-mutated neuroblastoma.

Journal: Cold Spring Harbor molecular case studies

Published: December 04, 2020

Showing 1-5 of 5

Last Updated: 09/26/2026